Tag: International Conference on Alzheimer’s & Parkinson Diseases 2021
Lilly’s donanemab reduces Alzheimer’s disease progression in Phase 2 trial
ALZ results revealed by Eli Lilly and Company at the recent 15th International Conference on Alzheimer's & Parkinson Diseases 2021 (AD/PD 2021) expand on...
